Cell News and Research

RSS

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

Findings hold great promise for potential use of ELABELA as therapeutic molecule for heart diseases

Scientists at A*STAR's Institute of Medical Biology and Institute of Molecular and Cellular Biology have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases. The hormone - which they have chosen to name ELABELA - is only 32 amino-acids long, making it amongst the tiniest proteins made by the human body.

9 Dec 2013

NYSCF, PersonalGenomes.org partner to identify genetic contributions to disease development

Today, the New York Stem Cell Foundation Research Institute and PersonalGenomes.org announced a partnership to identify genetic and environmental contributions to trait and disease development. Cell lines generated by NYSCF will complement genomic data and medical histories contributed by participants in the Harvard Personal Genome Project, creating a unique and powerful resource to help researchers identify causes of disease.

9 Dec 2013

New form of gene therapy shows promising outcomes for "bubble boy" disease

Researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated as part of an international clinical study of a new form of gene therapy. The mechanism used to deliver the gene therapy is designed to prevent the serious complication of leukemia that arose a decade ago in a similar trial in Europe, when one-quarter of boys treated developed the blood cancer.

9 Dec 2013

New study presents promising results for treatment of multiple myeloma

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Researchers uncover biological factor that may contribute to disparities in prostate cancer incidence

Researchers have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

MRI-guided SLA surgery proves safe and shows adequate efficacy for seizure control

MRI-Guided Stereotactic Laser Ablation of the hippocampus to control seizures in people with temporal lobe epilepsy may result in seizure control that approaches that from anterior temporal lobectory or selective amygdalohippocampectomy and better cognitive outcomes than any of the standard open resections, according to a study presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC.

9 Dec 2013

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Seizures in people with epilepsy are commonly treated with anti-epileptic drugs (AEDs) but 30-40 percent do not achieve adequate seizure control, predisposing them to severe health risks, impaired quality of life and higher healthcare costs.

9 Dec 2013

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

9 Dec 2013

Study helps explain why survival gap persists for African-Americans with head and neck cancer

A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations in black Americans, in addition to some chemical alterations affecting gene activity, which may help explain why the death rate among African-Americans from the most common form of head and neck cancer continues to hover some 18 percent higher above the death rate of whites with the same cancer.

9 Dec 2013

High frequency cell phone users have lower GPA, higher anxiety, and lower happiness in life

Today, smartphones are central to college students' lives, keeping them constantly connected with friends, family and the Internet. Students' cell phones are rarely out of reach whether the setting is a college classroom, library, recreational center, cafeteria or dorm room.

9 Dec 2013

Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain.

9 Dec 2013

Scientists receive 2013 Horwitz Prize for discoveries on how brain calculates location, navigation

Edvard and May-Britt Moser of the Norwegian University of Science and Technology (NTNU), and John O'Keefe, from University College London have been awarded the 2013 Louisa Gross Horwitz Prize for discoveries that have illuminated how the brain calculates location and navigation.

9 Dec 2013

Skin is capable of communicating with liver, say researchers

Researchers from the University of Southern Denmark have discovered that the skin is capable of communicating with the liver. The discovery has surprised the scientists, and they say that it may help our understanding of how skin diseases can affect the rest of the body.

9 Dec 2013

Cell News and Research

Adocia gets development and commercialization rights in nanotechnology for drug delivery

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

Findings hold great promise for potential use of ELABELA as therapeutic molecule for heart diseases

NYSCF, PersonalGenomes.org partner to identify genetic contributions to disease development

New form of gene therapy shows promising outcomes for "bubble boy" disease

New study presents promising results for treatment of multiple myeloma

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Researchers uncover biological factor that may contribute to disparities in prostate cancer incidence

MRI-guided SLA surgery proves safe and shows adequate efficacy for seizure control

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Study helps explain why survival gap persists for African-Americans with head and neck cancer

High frequency cell phone users have lower GPA, higher anxiety, and lower happiness in life

Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

Scientists receive 2013 Horwitz Prize for discoveries on how brain calculates location, navigation

Skin is capable of communicating with liver, say researchers

How to optimize your cell line development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms